STO Healthcare Biotechnology CANTA.ST

Cantargia AB (publ)

$ 2.16 0.56 %

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.

CEO: Hilde Hermansen Steineger - https://www.cantargia.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 20.82

Loading data...

CANTA.ST vs S&P500

Loading data...

No data available.

Quick ratio

8.09

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

3.38

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.64

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

77.69 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

67.79 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

11.88

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.00

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.63

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
5.57 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
7.52 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.00 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.